title: Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning?
authors.affiliation: From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N.); Stroke Outcomes Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX (T.A.K.); and Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (T.A.K.). gntaios@med.uth.gr.
authors.forename: George
authors.initials: G
authors.lastname: Ntaios
authors.affiliation: From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N.); Stroke Outcomes Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX (T.A.K.); and Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (T.A.K.).
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Kent
mesh_terms: D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance; D047495:PPAR gamma / Q000819:agonists; D000077205:Pioglitazone; D011236:Prediabetic State / Q000188:drug therapy; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone
keywords: diabetes mellitus; heart failure; insulin; pioglitazone; stroke